ProKidney Corp. (PROK)
1.83
-0.02
(-1.08%)
USD |
NASDAQ |
Sep 10, 16:00
1.83
0.00 (0.00%)
After-Hours: 20:00
ProKidney EPS Diluted (Quarterly) : -0.1524 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1524 |
| March 31, 2026 | -0.1412 |
| December 31, 2025 | -0.1369 |
| September 30, 2025 | -0.122 |
| June 30, 2025 | -0.1266 |
| March 31, 2025 | -0.1297 |
| December 31, 2024 | -0.1662 |
| September 30, 2024 | -0.142 |
| June 30, 2024 | -0.1648 |
| March 31, 2024 | -0.1557 |
| December 31, 2023 | -0.0952 |
| Date | Value |
|---|---|
| September 30, 2023 | -0.1783 |
| June 30, 2023 | -0.1412 |
| March 31, 2023 | -0.157 |
| December 31, 2022 | -0.1054 |
| September 30, 2022 | -0.1938 |
| June 30, 2022 | -0.3593 |
| March 31, 2022 | -1.097 |
| December 31, 2021 | -0.2221 |
| September 30, 2021 | -0.5375 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | -0.0002 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -1.355 |
| Oncolytics Biotech, Inc. | -0.0788 |
| Sangamo Therapeutics, Inc. | -0.0796 |
| Sarepta Therapeutics, Inc. | -0.0464 |
| Anixa Biosciences, Inc. | -0.0762 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -46.44M |
| Revenue (Quarterly) | 0.15M |
| Total Expenses (Quarterly) | 28.57M |
| Enterprise Value | 1.309B |
| Gross Profit Margin (Quarterly) | -866.0% |
| Profit Margin (Quarterly) | -30.96K% |
| Earnings Yield | -30.19% |
| Normalized Earnings Yield | -30.19 |